arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


DIABETIC MACULAR EDEMA

  Presented by the Johns Hopkins University School of Medicine

 

Neil M. Bressler, MD

OVERVIEW

The retina community is experiencing an influx of information for the management and treatment of retinal vein occlusions (RVO) and diabetic macular edema (DME). This assortment of data mainly comes from clinical trials which are designed to test and assess various treatments, provide dosing recommendations, and combinations thereof for different patient populations. This activity will provide retina specialists with these emerging findings and offer opportunities to analyze and discuss this new information as it relates to daily clinical practice and clinical decision-making. This activity will also feature interactive case studies that focus on the practical application of new treatments for patients with RVO and DME.

GOAL

The goal of this educational activity is to help retina specialists meet individual patients’ needs based on each patient’s unique risk/benefit profile for optimal visual outcomes.

INTENDED AUDIENCE

This activity is designed for retina specialists and other ophthalmologists who manage patients with macular edema. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant will demonstrate the ability to:

  • EVALUATE the results of the latest clinical trials for the management of patients with RVO.
  • EVALUATE the results of the latest clinical trials for the management of patients with DME and other aspects of diabetic retinopathy.
  • APPLY results from the latest clinical trials in RVO and DME in clinical case scenarios.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The estimated time to complete this activity: 30 minutes.

Release date: July 1, 2010. Expiration date: July 1, 2012.

HOW TO RECEIVE CREDIT OR CONTACT HOURS

The following interactive case activity consists of 3 sections: a pre-test, an interactive case with decision points, and a CME post-test with an evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the module.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require a signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Author
Neil M. Bressler, MD (Chair)
The James P. Gills Professor of Ophthalmology
Chief, Retina Division
Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Bressler reports receiving grants/research support from Abbott Medical Optics, Allergan, Inc, Bausch & Lomb Incorporated, Carl Zeiss Meditec, Inc, The EMMES Corporation, ForSight Labs, LLC, Genentech, Inc, Genzyme Corporation, Lumenis, Notal Vision, Novartis Pharmaceuticals Corporation, QLT Inc, Regeneron Pharmaceuticals, Inc, and Steba Biotech.

Planners
Neil M. Bressler, MD (Chair)
Dr Bressler reports serving as principal investigator for Abbott Medical Optics, Allergan, Inc, Bausch & Lomb Incorporated, Carl Zeiss Meditec, Inc, The EMMES Corporation, ForSight Labs, LLC, Genentech, Inc, Genzyme Corporation, Lumenis, Notal Vision, Novartis Pharmaceuticals Corporation, QLT Inc, Regeneron Pharmaceuticals, Inc, and Steba Biotech. Dr Bressler also reports that his spouse, Susan Bressler, MD, is a consultant for GlaxoSmithKline, Notal Vision, and Sightpath Medical and a co-investigator for Genentech, Inc, and Novartis Pharmaceuticals Corporation.

Susan B. Bressler, MD
Dr Bressler reports serving as co-investigator of grants for Genetech, Inc and Novartis Pharmaceutical Corporation; and as a consultant for GlaxoSmithKline, Notal Vision, and Sightpath Medical. Dr Bressler reports that her spouse, Neil M. Bressler, MD, is a principal investigator for Abbott Medical Optics, Allergan, Inc, Bausch & Lomb Incorporated, Carl Zeiss Meditec, Inc, The EMMES Corporation, ForSight Labs, LLC, Genentech, Inc, Genzyme Corporation, Lumenis, Notal Vision, Novartis Pharmaceuticals Corporation, QLT Inc, Regeneron Pharmaceuticals, Inc, and Steba Biotech.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Neil M. Bressler—bevacizumab, ranibizumab, and triamcinolone acetonide.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of the Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

Supported by an educational grant from Genentech, Inc.

procced to pretest
footer